Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 12;21(2):16.
doi: 10.1007/s11906-019-0915-1.

Weight Loss Medications in the Treatment of Obesity and Hypertension

Jordana B Cohen  1   2 , Kishore M Gadde  3
Affiliations
Review

Weight Loss Medications in the Treatment of Obesity and Hypertension

Jordana B Cohen et al. Curr Hypertens Rep. .

Abstract

Purpose of review: Weight loss is strongly associated with improvement in blood pressure; however, the mechanism of weight loss can impact the magnitude and sustainability of blood pressure reduction.

Recent findings: Five drugs-orlistat, lorcaserin, liraglutide, phentermine/topiramate, and naltrexone/bupropion-are currently approved for weight loss therapy in the USA. Naltrexone/bupropion results in an increase in in-office and ambulatory blood pressure compared to placebo. Other therapies are associated with modest lowering of blood pressure, and are generally well-tolerated; nonetheless, evidence is limited regarding their effect on blood pressure, particularly longitudinally, in individuals with hypertension. Although weight loss medications can be an effective adjunct to lifestyle modifications in individuals with obesity, there is limited evidence regarding their benefit with regard to blood pressure. Future studies evaluating the effectiveness of weight loss medications should include careful assessment of their short- and long-term impact on blood pressure in individuals with hypertension.

Keywords: Blood pressure; Hypertension; Obesity; Weight loss; Weight loss medication; Weight loss pharmacotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Dr. Cohen has no financial conflicts of interest to disclose.

References

    1. Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007–2008 to 2015–2016. JAMA 2018;319:1723–5. doi: 10.1001/jama.2018.3060. - DOI - PMC - PubMed

    1. ••The GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017;377:13–27. doi: 10.1056/NEJMoa1614362.

      This study analyzed data from >68 million persons to assess trends in overweight/obesity between 1980 and 2015. Additionally, the investigators quantified the burden of disease related to BMI, according to age, sex, cause, and BMI in 195 countries.

    1. Tremmel M, Gerdtham UG, Nilsson PM, Saha S. Economic burden of obesity: a systematic literature review. Int J Environ Res Public Health 2017;14:435. doi: 10.3390/ijerph14040435. - DOI - PMC - PubMed
    1. Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011;377:1085–95. doi: 10.1016/S0140-6736(11)60105-0. - DOI - PMC - PubMed
    1. Franceschini N, Gouskova NA, Reiner AP, Bostom A, Howard BV, Pettinger M, et al. Adiposity patterns and the risk for ESRD in postmenopausal women. Clin J Am Soc Nephrol 2015;10:241–50. doi: 10.2215/CJN.02860314. - DOI - PMC - PubMed

Substances